HUE047940T2 - Eritromelalgia kezelése - Google Patents
Eritromelalgia kezeléseInfo
- Publication number
- HUE047940T2 HUE047940T2 HUE15790622A HUE15790622A HUE047940T2 HU E047940 T2 HUE047940 T2 HU E047940T2 HU E15790622 A HUE15790622 A HU E15790622A HU E15790622 A HUE15790622 A HU E15790622A HU E047940 T2 HUE047940 T2 HU E047940T2
- Authority
- HU
- Hungary
- Prior art keywords
- erythromelalgia
- treatment
- erythromelalgia treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417497.3A GB201417497D0 (en) | 2014-10-03 | 2014-10-03 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE047940T2 true HUE047940T2 (hu) | 2020-05-28 |
Family
ID=51946794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15790622A HUE047940T2 (hu) | 2014-10-03 | 2015-10-02 | Eritromelalgia kezelése |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10231950B2 (hu) |
| EP (1) | EP3200783B1 (hu) |
| CY (1) | CY1122418T1 (hu) |
| DK (1) | DK3200783T3 (hu) |
| ES (1) | ES2751688T3 (hu) |
| GB (1) | GB201417497D0 (hu) |
| HR (1) | HRP20191434T1 (hu) |
| HU (1) | HUE047940T2 (hu) |
| LT (1) | LT3200783T (hu) |
| PL (1) | PL3200783T3 (hu) |
| PT (1) | PT3200783T (hu) |
| RS (1) | RS59479B1 (hu) |
| SI (1) | SI3200783T1 (hu) |
| WO (1) | WO2016051194A1 (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417497D0 (en) * | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| KR20190082253A (ko) * | 2016-11-02 | 2019-07-09 | 바이오젠 엠에이 인코포레이티드 | 신규한 투약 요법 |
| WO2019204136A1 (en) * | 2018-04-16 | 2019-10-24 | Biogen Ma Inc. | Methods of treating neuropathic pain |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| AU632494B2 (en) | 1988-05-20 | 1993-01-07 | F. Hoffmann-La Roche Ag | Immobilized sequence-specific probes |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP2001507921A (ja) | 1992-04-27 | 2001-06-19 | トラスティーズ オブ ダートマス カレッジ | 生物学的液体中の遺伝子配列の検出 |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| CN1098256C (zh) | 1996-04-12 | 2003-01-08 | G·D·瑟尔公司 | 作为cox－2抑制剂前药的取代的苯磺酰胺衍生物 |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US5866336A (en) | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| EE03680B1 (et) | 1996-07-18 | 2002-04-15 | Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. | Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| YU11900A (sh) | 1997-09-05 | 2002-11-15 | Glaxo Group Limited | Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2) |
| ES2228127T3 (es) | 1998-11-03 | 2005-04-01 | Glaxo Group Limited | Derivados de pirazolopiridina como inhibidores selectivos de cox-2. |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP2117538A1 (en) * | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| WO2014061970A1 (en) * | 2012-10-15 | 2014-04-24 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| CA2939549C (en) * | 2013-03-15 | 2020-08-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| GB201409851D0 (en) * | 2014-06-03 | 2014-07-16 | Convergence Pharmaceuticals | Diagnostic method |
| GB201417497D0 (en) * | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| KR102412146B1 (ko) * | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
-
2014
- 2014-10-03 GB GBGB1417497.3A patent/GB201417497D0/en not_active Ceased
-
2015
- 2015-10-02 DK DK15790622.3T patent/DK3200783T3/da active
- 2015-10-02 PT PT15790622T patent/PT3200783T/pt unknown
- 2015-10-02 ES ES15790622T patent/ES2751688T3/es active Active
- 2015-10-02 EP EP15790622.3A patent/EP3200783B1/en active Active
- 2015-10-02 PL PL15790622T patent/PL3200783T3/pl unknown
- 2015-10-02 RS RS20190994A patent/RS59479B1/sr unknown
- 2015-10-02 WO PCT/GB2015/052885 patent/WO2016051194A1/en active Application Filing
- 2015-10-02 LT LTEP15790622.3T patent/LT3200783T/lt unknown
- 2015-10-02 US US15/516,031 patent/US10231950B2/en active Active
- 2015-10-02 HU HUE15790622A patent/HUE047940T2/hu unknown
- 2015-10-02 SI SI201530856T patent/SI3200783T1/sl unknown
-
2019
- 2019-01-22 US US16/254,251 patent/US20190388391A1/en not_active Abandoned
- 2019-08-08 HR HRP20191434TT patent/HRP20191434T1/hr unknown
- 2019-10-31 CY CY20191101134T patent/CY1122418T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3200783T3 (pl) | 2020-01-31 |
| SI3200783T1 (sl) | 2020-03-31 |
| EP3200783A1 (en) | 2017-08-09 |
| LT3200783T (lt) | 2019-09-10 |
| ES2751688T3 (es) | 2020-04-01 |
| WO2016051194A1 (en) | 2016-04-07 |
| US20170304264A1 (en) | 2017-10-26 |
| US20190388391A1 (en) | 2019-12-26 |
| EP3200783B1 (en) | 2019-07-31 |
| DK3200783T3 (da) | 2019-08-05 |
| GB201417497D0 (en) | 2014-11-19 |
| HRP20191434T1 (hr) | 2020-10-02 |
| CY1122418T1 (el) | 2021-01-27 |
| PT3200783T (pt) | 2019-08-21 |
| RS59479B1 (sr) | 2019-12-31 |
| US10231950B2 (en) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250387A0 (en) | combined treatment | |
| IL248856A0 (en) | New treatment | |
| GB201405033D0 (en) | Combination therapy | |
| GB201608885D0 (en) | Treatment | |
| GB201522243D0 (en) | Treatment | |
| GB201502137D0 (en) | Treatment | |
| ZA201702522B (en) | Combination therapy | |
| SG11201601030VA (en) | Massager | |
| GB201508841D0 (en) | Treatment | |
| GB201402179D0 (en) | Surface treatment | |
| PL3200783T3 (pl) | Leczenie erytromelalgii | |
| ZA201608217B (en) | Combination therapy | |
| GB201411027D0 (en) | Treatment | |
| GB201503008D0 (en) | Treatment | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| GB201609683D0 (en) | Treatment | |
| GB201518349D0 (en) | Treatment | |
| GB201515739D0 (en) | Treatment | |
| GB201514008D0 (en) | Treatment | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201412411D0 (en) | Treatment | |
| GB201400241D0 (en) | Treatment |